Hospital Implementation Playbook

Tabulate annual volume of relevant procedures: free flap reconstruction (post-mastectomy, head-and-neck, lower extremity), digital replantation, ear/scalp replantation, vascularized composite allotransplantation if applicable. Threshold for sustainable program: typically 20+ such procedures per year; below this, partnership with a referral center may be more cost-effective than internal program.

Confirm institutional capability: (a) microsurgical training of surgical staff (ASRM membership or equivalent); (b) post-operative monitoring infrastructure (intensive care unit or step-down with q4h nursing capability); (c) hospital pharmacy capability to support 24/7 antibiotic prophylaxis; (d) institutional review board (IRB) familiarity with biologic device regulations.

Identify key stakeholders before formal proposal: Chief of Plastic Surgery (or equivalent reconstructive specialty), Chief of Pharmacy, Director of Nursing Quality, Infection Prevention Officer, Hospital CFO (for cost-impact analysis), and Risk Management. Conduct 30-minute informal discussions with each to identify concerns before formal proposal.

Identify 2-3 peer institutions currently running hirudotherapy programs. Request site visits or video conferences. Document: their patient volume, staffing model, pharmacy workflow, billing approach, outcome metrics, lessons learned. ASH can facilitate introductions to interested peer institutions.

Synthesize Phase 1 findings into a 2-page decision memo for Hospital Executive Committee. Include: estimated annual case volume, capital costs (low — primarily setup), operational costs (ongoing — primarily leech procurement and antibiotic prophylaxis), expected revenue (limited for off-label; covered within DRG for FDA-cleared indications), and risk profile (low — well-established intervention).

A single program champion — typically a senior microsurgical attending — owns the operational launch. Champion responsibilities: protocol development, staff training, quality metrics ownership, escalation pathway, ongoing institutional advocacy. Without a clear champion, programs typically fail to launch.

Establish a 5–7 member working group: surgical champion (chair), pharmacy representative, OR nursing leadership, floor/step-down nursing leadership, infection prevention specialist, hospital quality officer, and an administrative coordinator. Meeting cadence: biweekly during pre-launch, monthly during first 6 months, quarterly thereafter.

Working group develops a 3–5 page Program Charter covering: (a) scope (which patient populations, which indications), (b) clinical protocols with version control, (c) stakeholder responsibilities with named roles, (d) quality metrics with target values, (e) escalation pathway for complications, (f) annual review and continuous improvement plan.

Charter requires sign-off from: Chief Medical Officer, Chief Nursing Officer, Pharmacy Director, Infection Prevention Officer, Hospital Compliance Officer, and (often) Risk Management. Each signature reflects departmental commitment to the protocol. Skipping any of these creates fragility.

Develop internal communications: (a) staff newsletter announcement, (b) Grand Rounds presentation in surgical department, (c) pharmacy in-service for antibiotic prophylaxis, (d) nursing in-service for application and monitoring, (e) physician FAQ document for non-surgical referring physicians.

Document criteria for hirudotherapy candidacy: Inclusion — venous congestion confirmed clinically (flap color, capillary refill, bleeding-on-pinprick) AND microvascular re-anastomosis not immediately feasible. Absolute exclusion — hemophilia, severe anemia (Hgb<8), active septicemia, prior anaphylaxis to leech SGS, hematologic malignancies, decompensated liver disease. Relative exclusion — anticoagulation (case-by-case with team coordination), diabetes (modified prophylaxis), immunosuppression (extended prophylaxis), pregnancy (rarely justified).

Standardized checklist before first leech application: (a) Surgical team confirmation of venous congestion diagnosis; (b) Hematologic labs (CBC, coagulation, hemoglobin); (c) Antibiotic prophylaxis initiated minimum 1 hour prior; (d) Informed consent reviewed (with patient or appropriate decision-maker); (e) Emergency anaphylaxis medications bedside; (f) Wound dressing supplies prepared; (g) Patient and family education provided about expected post-detachment bleeding.

Step-by-step application: (1) Hand hygiene + gloves; (2) Leech transferred from supplier vial to sterile saline-rinsed container; (3) Leech placed on target site via small medical apparatus (cup, tube); (4) Wait for spontaneous attachment (typically 1-10 minutes); (5) Monitor patient comfort; (6) Allow feeding to spontaneous detachment (20-60 minutes typical); (7) Euthanize used leech in 70% ethanol (single-patient single-use); (8) Apply absorbent dressing; (9) Document time, leech count, patient response.

Post-application monitoring frequency: vital signs q15min for first hour, then q1h for 4 hours, then q4h until next application or 24 hours post-final leech. Specific monitoring: (a) Bleeding rate and total volume; (b) Tissue assessment (color, capillary refill, temperature, edema, bleeding-on-pinprick); (c) Patient comfort and any reaction (urticaria, dizziness, anxiety); (d) Vital signs trending.

Documented protocols for: (a) Excessive bleeding — pressure dressings, topical hemostatic agents, transfusion criteria; (b) Anaphylaxis — IM epinephrine 0.3-0.5 mg, IV fluids 20 mL/kg bolus, IV diphenhydramine 25-50 mg, ED activation; (c) Aeromonas infection signs — broad-spectrum antibiotic escalation, infectious disease consult; (d) Inadequate response — reassessment for surgical re-exploration vs. continued conservative management.

Build standardized EMR order set: Ciprofloxacin 500 mg PO BID + TMP-SMX DS 160/800 mg PO BID starting prior to first leech application and continuing for therapy duration + 24 hours. For immunocompromised patients: extend duration to 10-14 days. For IV-only patients: ciprofloxacin 400 mg IV q12h + ceftriaxone 2 g IV q24h as IV alternative. Include automatic infectious disease consultation order for breakthrough infection.

EMR alerts for major drug interactions: ciprofloxacin + tizanidine (contraindicated); ciprofloxacin + warfarin (INR elevation); ciprofloxacin + theophylline (toxicity); TMP-SMX + ACE inhibitors (hyperkalemia); TMP-SMX + warfarin (INR elevation). Pharmacist verification required before first dose.

Establish supplier account with one or more FDA-cleared suppliers: Ricarimpex SAS (France), Biopharm UK Ltd. (Wales), Carolina Biological Supply Co. (NC). Recommended: primary + backup supplier. Lead time for non-emergency orders: typically 2-3 business days. Emergency orders: same-day overnight available from most suppliers. Storage: refrigerated 4-15°C in dedicated container with monitored temperature.

Pharmacy maintains rolling 1-week supply for active patients + emergency-stock 4-leech minimum at all times. Track expiration (typical viability 30 days from receipt). Implement FIFO rotation. Document destruction logs for expired leeches (70% ethanol, biohazard disposal). Annual reconciliation of leech use vs. patient cases.

After single-patient use: leech euthanized in 70% ethanol, placed in red bag biohazard, sent for biomedical waste incineration. Document each leech disposal with patient ID, date, and used-leech count. This regulatory requirement protects against re-use and provides audit trail.

Identify 6-10 designated nurses across shifts (day, evening, night, weekend) who will be trained and competent to perform leech application. Avoid model where 'anyone' applies leeches — competency requires repetition. Reserve initial cases for designated nurses; expand pool over time.

Develop 2-hour didactic course covering: (a) Why hirudotherapy works and when; (b) Aeromonas infection risk and prophylaxis essentials; (c) Application technique with video demonstration; (d) Monitoring protocols and warning signs; (e) Patient communication including what to expect; (f) Documentation and quality reporting. Test competency with written exam (minimum passing 80%).

Conduct hands-on skills lab using non-medical training leeches (Carolina Biological offers educational leeches separately from medical-grade). Each designated nurse performs: 3 application practices, 2 monitoring scenarios (including a simulated bleeding complication), 1 anaphylaxis response simulation. Sign off competency.

First 5 patient cases for each designated nurse are performed under supervision of charge nurse or program champion. Document each case with structured debrief: technique adequacy, monitoring quality, patient communication assessment. After 5 supervised cases, designated nurse operates independently.

Annual recertification: written knowledge exam + simulated competency lab. Quarterly skills refresh for low-volume nurses. Pre-shift huddle includes leech-therapy patients with brief case review.

Standardize microbiological surveillance: (a) Wound cultures from any hirudotherapy patient with signs of infection; (b) Blood cultures for any febrile hirudotherapy patient; (c) Annual environmental sampling of leech vials/storage water from supplier (correlation with isolate susceptibility); (d) Susceptibility testing reported to ciprofloxacin, TMP-SMX, ceftriaxone, gentamicin, ceftazidime, meropenem.

Annual stewardship review: documented prophylaxis duration appropriateness (24h continuation standard, 10-14 day extension only when indicated), drug selection (cipro+TMP-SMX standard, alternatives only for documented allergy/contraindication), de-escalation when sensitivities allow.

Maintain registry of breakthrough infections despite prophylaxis. Track: (a) Specific isolate identification; (b) Antibiotic susceptibility profile; (c) Suspected source (supplier batch vs. environmental contamination); (d) Treatment outcome. Annual review identifies trends informing protocol adjustments.

Quarterly contact with leech suppliers regarding: (a) Their internal Aeromonas surveillance results; (b) Any product safety notices; (c) Antibiotic susceptibility trends in their facilities; (d) Quality control deviations. Maintain documentation per Joint Commission supplier oversight requirements.

Standard precautions per OSHA Bloodborne Pathogen Standard: gloves required for all leech handling and bite-site care, gowns and eye protection during heavy bleeding management. Hand hygiene compliance: pre- and post-application 100% target.

Track for every case: (a) Flap salvage rate at 7 days post-leech-initiation; (b) Aeromonas infection rate (target <5%); (c) Transfusion rate; (d) Patient-reported satisfaction (post-discharge); (e) Length of stay attributable to hirudotherapy.

Per FDA 21 CFR 803 (Medical Device Reporting): report any serious adverse events to FDA MedWatch within required timeframes. Internal incident reporting for: anaphylaxis episodes, Aeromonas infections, transfusion reactions, leech application errors, unexpected mortality.

Monthly quality review meeting (working group): aggregate metrics review, individual case M&M for any complication, protocol amendment proposals, training/education needs identified. Document discussions and decisions.

Annual report covering: (a) Total patient volume; (b) Outcome metrics with year-over-year comparison; (c) Budget and revenue performance; (d) Staff training compliance; (e) Compliance audits (FDA, Joint Commission); (f) Strategic plan for following year.

Participate in ASH-facilitated benchmark program (when established): de-identified outcome data shared with peer institutions for comparative quality assessment. Initial U.S. benchmark cohort being developed; institutions can contact ASH for inclusion.

Primary diagnosis codes for hirudotherapy contexts: T87.50XA (Complications of microvascular anastomosis, initial); T87.51XA (Complication of microvascular flap, initial); I96 (Gangrene, not elsewhere classified, for replantation context). Confirm code applicability with coding leadership.

CPT code: No hirudotherapy-specific CPT code currently exists. Most institutions bill under: (a) unlisted-procedure code with manual review (97799 — unlisted physical medicine/rehabilitation service; or 99499 — unlisted evaluation and management service); (b) for hospital outpatient settings, HCPCS C-codes may apply. Best practice: consult Revenue Cycle leadership for institution-specific coding strategy.

Per case documentation: (a) Diagnosis with ICD-10 code; (b) Medical necessity (venous congestion clinical signs, alternative treatments considered); (c) Leech application details (time, count per session, total session count); (d) Antibiotic prophylaxis (drug, dose, duration); (e) Patient response and outcome; (f) Discharge condition with follow-up plan.

FDA-cleared microsurgical application typically covered under broader surgical admission DRG. Off-label applications (knee OA, varicose veins, etc.) typically not reimbursed by Medicare/Medicaid/commercial insurance and require patient payment arrangement. Document financial counseling for off-label patients.

Pharmacy charges leech procurement cost: typically $25-30 per leech wholesale; institutional markup variable. Document leech use per case for billing and inventory reconciliation.

Confirm use only of FDA-cleared suppliers (Ricarimpex K040187, Biopharm UK K132958, Carolina Biological K140907). Maintain documentation chain demonstrating chain-of-custody. Per 21 CFR 803 (Medical Device Reporting): report serious adverse events to FDA MedWatch within required timeframes. Note: as of December 30, 2024, FDA jurisdiction transferred from CDRH to CBER; both BK and K tracking numbers may be referenced during transition.

Relevant Joint Commission standards: (a) MM (Medication Management) — antibiotic prophylaxis protocols, supplier oversight; (b) IC (Infection Control) — Aeromonas surveillance, hand hygiene, PPE; (c) RC (Record of Care) — documentation completeness; (d) UP (Universal Protocol) — site marking and time-out for application sites. Document compliance for accreditation visits.

Confirm state-specific requirements: (a) Scope of practice for who can apply leeches (typically RN under physician supervision; varies by state); (b) Biologic substance reporting requirements (some states); (c) Pharmacy licensing for storing/distributing live medical devices. Consult state board of nursing and state department of health.

Standardized informed consent form includes: (a) FDA-cleared status for cleared indications OR explicit off-label disclosure for non-cleared uses; (b) Aeromonas infection risk (with and without prophylaxis); (c) Expected bleeding pattern; (d) Permanent scarring; (e) Anaphylaxis risk; (f) Alternative treatments discussed. Witnessed and documented per institutional policy.

Written Exposure Control Plan covering hirudotherapy includes: (a) Annual review; (b) Required PPE (gloves, eye protection, gowns); (c) Engineering controls (sharps containers, biohazard disposal); (d) Post-exposure protocol; (e) Employee training documentation.

Year 1 typical volume: 10-25 patients for community hospital, 50-150+ for tertiary academic center. Year 2-3 growth strategies: (a) Internal awareness campaigns to non-surgical specialties; (b) External referral relationships with rural hospitals (transfer pathway); (c) Subspecialty expansion (e.g., vascularized composite allotransplantation); (d) Off-label outpatient program if institutional capability supports.

Document program cost-effectiveness annually: (a) Direct costs (leech procurement, antibiotic prophylaxis, additional nursing time); (b) Indirect costs (training, supplies, IT); (c) Comparison to alternative interventions (re-anastomosis, alternative pharmacologic salvage); (d) Outcome benefits monetized (avoided amputation cost, avoided revision surgery, reduced length of stay). Frame for hospital leadership as ROI.

Year 2+ consider research collaboration: (a) Multicenter case-series registry participation; (b) Quality improvement publications; (c) IRB-approved protocol research; (d) Industry-sponsored trials (rare); (e) Foundation-grant-funded research. Research integration enhances program prestige and may attract additional funding.

Avoid single-champion dependency: identify and develop secondary program champions among rising surgical leaders. Cross-train nursing leadership. Document all protocols and institutional knowledge in non-proprietary format that survives staff turnover.

Annual review of: (a) Emerging evidence (new RCTs, systematic reviews); (b) Updated professional society guidelines; (c) New supplier options or pricing changes; (d) Regulatory updates (FDA jurisdiction changes, new guidance documents); (e) Technology integrations (EMR templates, monitoring systems). Update protocols accordingly with version control.